These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 5736354)

  • 1. [Effect of physalaemine on lacrimal and salivary secretion in Sjögren's syndrome].
    Sala G; Cortellaro M; Ballabio CB
    Reumatismo; 1968; 20(5):594-6. PubMed ID: 5736354
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of bromhexin on the functional deficiency of the lacrimal apparatus and the salivary glands in Sjogren's syndrome].
    Isager H; Frost-Larsen K; Manthorpe R; Westergaard L
    Med Monatsschr; 1977 Dec; 31(12):582-3. PubMed ID: 593225
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of physalaemin in the treatment of Sjogren's disease].
    Tamborini A; Perrotta P
    Ann Ottalmol Clin Ocul; 1969 Dec; 95(12):945-60. PubMed ID: 5408524
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trial of ambroxol (Mucosolvan) in Sjögren's syndrome.
    Ichikawa Y; Tokunaga M; Shimizu H; Moriuchi J; Takaya M; Arimori S
    Tokai J Exp Clin Med; 1988 Aug; 13(3):165-9. PubMed ID: 2978189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A method of treating conjunctivitis sicca and Sjögren's disease with a secretolytic].
    Grosse-Ruyken FJ
    Klin Monbl Augenheilkd; 1973 Apr; 162(4):540-3. PubMed ID: 4724007
    [No Abstract]   [Full Text] [Related]  

  • 6. [Original therapeutic endeavor for the Gougerot-Sjögren syndrome].
    Bonnet M; Moulin J; Girod M; Gouillon L; Biard L
    Bull Soc Ophtalmol Fr; 1969; 69(5-6):615-22. PubMed ID: 5399676
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract]   [Full Text] [Related]  

  • 8. Prednisone and piroxicam for treatment of primary Sjögren's syndrome.
    Fox PC; Datiles M; Atkinson JC; Macynski AA; Scott J; Fletcher D; Valdez IH; Kurrasch RH; Delapenha R; Jackson W
    Clin Exp Rheumatol; 1993; 11(2):149-56. PubMed ID: 8508556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome.
    Zoukhri D; Kublin CL
    Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):925-32. PubMed ID: 11274068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of lacrimal gland improvement by NA-872 in Sjögren's syndrome.
    Manthorpe R; Frost-Larsen K; Isager H; Prause JU
    Acta Ophthalmol (Copenh); 1981 Jun; 59(3):428-9. PubMed ID: 7034455
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new treatment for reduced tear production].
    Tiburtius H; Merker HJ
    Klin Monbl Augenheilkd; 1973 Apr; 162(4):535-9. PubMed ID: 4724006
    [No Abstract]   [Full Text] [Related]  

  • 13. Vascular changes in major and lingual minor salivary glands in primary Sjögren's syndrome.
    Takahashi H; Tezuka F; Fujita S; Okabe H
    Anal Cell Pathol; 1995 Dec; 9(4):243-56. PubMed ID: 8616101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate-day steroid therapy for patients with primary Sjögren's syndrome.
    Tabbara KF; Frayha RA
    Ann Ophthalmol; 1983 Apr; 15(4):358-61. PubMed ID: 6660708
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome.
    Tsubota K; Fujita H; Tadano K; Takeuchi T; Murakami T; Saito I; Hayashi Y
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):101-10. PubMed ID: 11133854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
    Vale DL
    Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8
    Zhou H; Yang J; Tian J; Wang S
    Front Immunol; 2020; 11():602823. PubMed ID: 33584670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome.
    Azuma M; Ashida Y; Tamatani T; Motegi K; Takamaru N; Ishimaru N; Hayashi Y; Sato M
    J Rheumatol; 2006 May; 33(5):912-20. PubMed ID: 16652422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of steroid hormone on the salivary and lacrimal secretions in Sjögren's syndrome (author's transl)].
    Ichikawa Y; Yamauchi K; Shimizu Y; Arimori S
    Ryumachi; 1979 Feb; 19(1):15-22. PubMed ID: 424901
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren's syndrome.
    Pijpe J; Kalk WW; Vissink A
    J Rheumatol; 2003 Jan; 30(1):206-7; author reply 207. PubMed ID: 12508418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.